• Home
  • Category
  • Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market By Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End-User (Hospitals, Clinics, Homecare Settings), & Region for 2024-2031

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Chronic Obstructive Pulmonary Disease Market By Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End-User (Hospitals, Clinics, Homecare Settings), & Region for 2024-2031

Chronic Obstructive Pulmonary Disease Market Valuation – 2024-2031

Rising incidence of COPD among populations across the globe is propelling the adoption of chronic obstructive pulmonary disease. The increasing tobacco consumption among young people & rising public awareness of the usage of generic drugs is driving the market size surpass USD 21.17 Billion valued in 2024 to reach a valuation of around USD 35.3 Billion by 2031.

In addition to this, increasing expenditure on healthcare is giving services in emerging countries is spurring up the adoption of chronic obstructive pulmonary disease. Growing R&D investment by the government and large players is enabling the market grow at a CAGR of 7.28% from 2024 to 2031.

Chronic Obstructive Pulmonary Disease MarketDefinition/ Overview

Do you often struggle with breathing, coughing, or feeling winded? If so, you may have a condition called chronic obstructive pulmonary disease (COPD). It's like having a persistent blockage in your airways, making it tough to breathe. COPD has two main types. Chronic bronchitis is like a traffic jam in your bronchial tubes, which carry air to your lungs. They get inflamed and swollen, and your body makes too much mucus, blocking the passageways. It's like trying to breathe through a clogged straw. Emphysema is another type of COPD. It's like your air sacs at the bottom of your lungs have burst like tiny balloons. Imagine an upside-down tree, where your windpipe is the trunk and the bronchial tubes are the branches. The air sacs, or alveoli, are like leaves. In emphysema, these leaves are damaged, making it harder for air to flow in and out. Smoking is the main culprit behind most COPD cases, so quitting is super important. Air pollution and other stuff in the air we breathe can also contribute. And if you have COPD, you're more likely to get other health problems like heart disease or lung cancer. It's a serious condition, but taking care of yourself and following your doctor's advice can help you manage it and live a fulfilling life.

Chronic Obstructive Pulmonary Disease (COPD) treatment focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Key components include bronchodilators to relax airway muscles and improve airflow, inhaled corticosteroids to reduce inflammation, and combination inhalers for enhanced efficacy. Pulmonary rehabilitation programs, encompassing exercise training, nutrition advice, and education, are crucial for patient empowerment and functional improvement. Supplemental oxygen therapy may be necessary for severe cases. Additionally, smoking cessation is vital to halt disease progression, while vaccinations and regular monitoring help prevent exacerbations and manage comorbidities effectively.

The future of COPD treatment will focus on personalized medicine, advanced drug delivery systems, and innovative therapies. Key trends include biologics targeting specific inflammatory pathways, gene therapy and regenerative medicine for lung tissue repair, digital health technologies like telemedicine and remote monitoring, and novel inhaler technologies and drug formulations. These advancements aim to improve outcomes and quality of life for COPD patients, enhancing patient management and adherence to treatment plans.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Rising Awareness of Chronic Obstructive Pulmonary Disease (COPD) Increase Adoption of Chronic Obstructive Pulmonary Disease?

As more people become aware of COPD, which is a serious lung disease, doctors and patients around the world are getting better at recognizing and diagnosing it. This is critical because it enables people with COPD to receive treatment sooner, which can improve their outcomes. As a result, there is a growing need for better ways to diagnose COPD, more effective treatments, and more research to understand and combat this disease. This changing landscape highlights the significance of education and proactive healthcare measures to reduce the impact of COPD on individuals and the healthcare system. This, in turn, is propelling the growth of the market for COPD-related products and services.

COPD is a major health problem around the world. It's caused by things like smoking, breathing in harmful stuff at work, and bad air quality inside homes. Smoking is still the biggest cause of COPD, especially as more adults are smoking around the globe. That's why we need better programs to help people quit smoking and stricter rules to keep tobacco away from people. Other things that can raise your chances of getting COPD include breathing in fumes and dust at work and breathing in dirty air at home. We need to make sure there are rules in place and that workplaces are safe so that people aren't exposed to these hazards as much. By doing these things, we can lower the number of people who get COPD and make their lives better. It'll also save our healthcare system money in the long run.

Advancements in diagnostic technologies like spirometry, CT scans, and biomarker testing have significantly improved the management of Chronic Obstructive Pulmonary Disease (COPD). These technologies enable early identification, personalized treatment plans, and improved symptom control. Additionally, therapeutic options like bronchodilators, corticosteroids, and biologic medicines have enhanced the quality of life for COPD patients. For instance, in February 2021, are conducting a Phase III clinical trial to evaluate the effectiveness and safety of itepekimab in reducing acute COPD exacerbations in former smokers, with the trial set to conclude in July 2024.

Will Rising Side Effects of Drugs Used in Treating Chronic Obstructive Pulmonary Disease (COPD) Restrain Its Application?

The rising side effects of drugs used in treating Chronic Obstructive Pulmonary Disease (COPD) significantly hinder market growth. According to the National Center for Biotechnology Information, medications such as inhaled steroids can cause oral infections, bruising, and hoarseness, which deter patient compliance and limit market expansion. Additionally, COPD patients on these medications are prone to respiratory infections like flu, colds, and pneumonia, further complicating their treatment and increasing healthcare costs.

Moreover, the complexity of COPD and the variability in patient response to treatments make drug development particularly challenging. Clinical trials, such as the Phase II TERRANOVA and GALATHEA studies, often struggle to demonstrate efficacy and safety, further impeding progress in the COPD market. This uncertainty in drug development discourages investment and slows the introduction of new therapies.

The development of new drugs for COPD is fraught with challenges, including high failure rates in clinical trials. For instance, in May 2019, benralizumab, an asthma drug, failed to reduce annual COPD exacerbation rates in patients with moderate to very severe COPD. Such setbacks highlight the difficulties in discovering effective treatments, limiting market growth prospects.

Complications associated with COPD, including depression, heart problems, high blood pressure in lung arteries, and lung cancer, also pose challenges to effective management and market growth. The severity of these complications necessitates comprehensive treatment approaches, which are often costly and resource-intensive, restraining market growth.

Category-Wise Acumens

Which Factors Contribute to the Dominance of Drugs Segment in Chronic Obstructive Pulmonary Disease Market?

The drugs segment dominates the chronic obstructive pulmonary disease (COPD) market, primarily due to the widespread use of bronchodilators. Bronchodilators, both short-acting and long-acting, hold a largest market share. They are crucial for managing COPD symptoms by relaxing airways and providing rapid relief from bronchospasms and exacerbations. The inhaled delivery method enhances patient compliance, making them a preferred choice for both patients and healthcare providers. As COPD progresses and lung function declines, bronchodilators become even more significant in managing symptoms and preventing exacerbations.

Corticosteroids are essential COPD drugs that reduce airway inflammation and mucus production. They are often used in combination with bronchodilators, particularly in severe COPD patients or those with frequent exacerbations. They help alleviate symptoms and improve lung function over time, but long-term use may have potential side effects, requiring careful healthcare management.

Phosphodiesterase type 4 (PDE4) inhibitors represent a newer addition to COPD treatment options. These medications work by reducing inflammation and relaxing the airways, similar to corticosteroids but through a different mechanism. PDE4 inhibitors are typically prescribed for patients with severe COPD and a history of exacerbations despite bronchodilator and corticosteroid therapy. Their role in managing COPD involves improving lung function and reducing exacerbation frequency, contributing to overall disease control and patient well-being.

The COPD market comprises various drug classes, including bronchodilators for immediate symptom relief, corticosteroids for inflammation management, and PDE4 inhibitors for symptom relief, each playing a crucial role in managing COPD symptoms and enhancing patient outcomes.

Which Factors Enhance the Use of Chronic Obstructive Pulmonary Disease in Hospitals?

Hospitals dominate the chronic obstructive pulmonary disease (COPD) market, with specialized departments like pulmonology and respiratory therapy, and advanced diagnostic capabilities like pulmonary function tests and imaging, ensuring accurate diagnosis and disease monitoring.

Hospitals offer a multidisciplinary approach to COPD management, involving pulmonologists, respiratory therapists, nurses, and rehabilitation specialists. They provide comprehensive care, addressing both medical and supportive needs. They offer a range of COPD treatments, including bronchodilators, corticosteroids, oxygen therapy, and surgical interventions. Hospitals also participate in clinical trials for innovative therapies.

Hospitals provide 24/7 emergency services, crucial for COPD patients experiencing sudden exacerbations or respiratory distress. This accessibility ensures prompt medical intervention and reduces morbidity and mortality associated with severe COPD complications.

Gain Access into Chronic Obstructive Pulmonary Disease Market Report Methodology

Country/Region-wise Acumens

Will Rising Prevalence of COPD in North America Mature Chronic Obstructive Pulmonary Disease Market?

North America stands out as a dominant force in the global chronic obstructive pulmonary disease (COPD) market for several compelling reasons. The region boasts a high prevalence of COPD, attributed partly to historical smoking rates and environmental factors. This prevalence drives substantial demand for COPD treatments and healthcare services, making it a significant contributor to the market’s size and growth.

North America benefits from advanced healthcare infrastructure and robust pharmaceutical industry capabilities. This infrastructure supports comprehensive diagnostic capabilities, including advanced imaging and pulmonary function tests, crucial for accurate COPD diagnosis and monitoring. Moreover, the region’s strong research and development ecosystem fosters continuous innovation in COPD therapies, ensuring patients have access to cutting-edge treatments and medications.

Also, efforts to raise public awareness about public health and implement smoking cessation programs in countries such as the United States and Canada are aimed at reducing risk factors for COPD and improving early detection. These initiatives contribute to improved disease management and outcomes, further solidifying North America’s position as a leader in the global COPD market.

Furthermore, healthcare policies and reimbursement frameworks in North America facilitate access to COPD treatments, including bronchodilators, corticosteroids, and biologics. This accessibility ensures that COPD patients receive timely and appropriate care, enhancing treatment adherence and overall health outcomes.

Will Increasing Air Pollution in Asia Pacific Drive the Growth of Chronic Obstructive Pulmonary Disease Market?

The Asia-Pacific region is expected to witness significant growth in the drugs segment of the chronic obstructive pulmonary disease (COPD) market during the forecast period due to the rising prevalence of COPD. Increasing air pollution and high smoking rates in countries like China and India contribute to a growing patient population, driving demand for effective treatments.

A rising prevalence of respiratory distress conditions is a major driver in the region. According to the World Health Organization (WHO), over 90% of COPD-related deaths occur in low and middle-income countries, highlighting the critical need for effective treatments in Asia-Pacific.

Moreover, the presence of a large aging population in the region, which is more susceptible to COPD, is fueling the demand for maintenance and rescue medications. This demographic trend is a key driver of market growth in the drugs segment.

Pharmaceutical companies are increasingly focusing on the Asia-Pacific market due to its high growth potential. Investments in local manufacturing and distribution networks, along with strategic partnerships, are expanding the availability and affordability of COPD drugs, thereby supporting market expansion in the region.

Competitive Landscape

The competitive landscape of the chronic obstructive pulmonary disease (COPD) market is characterized by intense competition and rapid innovation. Companies are focusing on developing advanced drug formulations and delivery systems to improve patient outcomes and adherence. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their market presence and leverage synergistic capabilities. Additionally, substantial investments in research and development, along with an emphasis on personalized medicine and biologics, are driving the evolution of treatment options, making the market highly dynamic and competitive. Some of the prominent players operating in the chronic obstructive pulmonary disease market include

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline (GSK)
  • Novartis
  • Merck & Co.
  • Pfizer
  • Teva Pharmaceuticals
  • Sanofi
  • Mylan
  • Chiesi Farmaceutici
  • Sunovion Pharmaceuticals
  • Orion Corporation
  • Cipla
  • Reddy’s Laboratories
  • Vectura Group
  • Circassia Pharmaceuticals
  • Theravance Biopharma
  • Verona Pharma
  • Glenmark Pharmaceuticals
  • Pulmatrix

 Latest Developments

  • In January 2022, A phase 4 study comparing Yupelri (revefenacin) and Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD) is underway. The study assesses the safety of these two approved daily COPD maintenance treatments. Yupelri, a bronchodilator developed by Theravance Biopharma and Mylan, relaxes and widens lung airways, making breathing easier. It is available as an inhalable solution via a nebulizer.
  • In November 2021, AstraZeneca sold the rights to commercialize Tudorza (Eklira) and Duaklir to Swiss pharmaceutical business Covis Pharma Group for US$ 270 million. The products are intended for the treatment of chronic obstructive pulmonary disease (COPD).

Report Scope

REPORT ATTRIBUTESDETAILS
Study Period

2021-2031

Growth Rate

CAGR of ~7.28% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2021-2023

Forecast Period

2024-2031

Quantitative Units

Value in USD Billion

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Type
  • Treatment Type
  • End-User
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK), Novartis, Merck & Co., Pfizer, Teva Pharmaceuticals, Sanofi, Mylan, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Orion Corporation, Cipla, Reddy’s Laboratories, Vectura Group, Circassia Pharmaceuticals, Theravance Biopharma, Verona Pharma, Glenmark Pharmaceuticals, Pulmatrix

Customization

Report customization along with purchase available upon request

Chronic Obstructive Pulmonary Disease Market, By Category

Type

  • Chronic Bronchitis
  • Emphysema

Treatment Type

  • Drugs
  • Bronchodilator Monotherapy
  • Short-Acting Beta2-Agonists (SABAS)
  • Long-Acting Beta2-Agonists (LABAS)
  • Anti-Cholinergic Agents
  • Anti-Inflammatory Drugs
  • Oral And Inhaled Corticosteroids
  • Anti-Leukotrienes
  • Surgery
  • Lung Volume Reduction Surgery (LVRS)
  • Lung Transplant, Bullectomy
  • Others
  • Oxygen Therapy

End-User

  • Hospitals
  • Homecare Settings
  • Clinics
  • Others

Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Research Methodology of Market Research

Related Reports

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email